Structure Therapeutics CEO Raymond Stevens Named to PharmaVoice 100

SAN FRANCISCO & SHANGHAI–(BUSINESS WIRE)–Structure Therapeutics, a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that Raymond Stevens, Ph.D., Chief Executive Officer, has been named to the PharmaVoice 100 � an annual list that recognizes the most inspiring people in the life-sciences industry.

“I am proud to be selected in this year’s PharmaVoice 100 and to join a remarkable group of leaders who have shared this honor,” said Dr. Stevens. “I consider myself lucky to work with such a talented team at Structure Therapeutics as we advance our novel oral small molecule medicines and overcome the limitations of biologics using our next generation structure-based drug discovery platform.”

PharmaVoice100 honorees are nominated by its readers and evaluated by the PharmaVoice team. This year’s honorees include Legacy Leaders, Tech Wizards, Innovators, Disrupters, Entrepreneurs, and DE&I Champions.

“It is always an honor to showcase these inspiring individuals, whose leadership over the past 18 months has been more important than ever to make sure their teams, the patients they serve, and their organizations continue to excel at the highest levels possible,” said Taren Grom, PharmaVoice Editor in Chief Emeritus.

Since 2005, the PharmaVoice 100 – and Red Jacket honorees – have become one of the publication’s most anticipated features. PharmaVoice developed the only awards program in the industry to recognize individuals of all ages representing all sectors of the life-sciences industry – from academia to nonprofit organizations to big pharma to emerging biotech companies to technology companies to commercial organizations that provide molecule-to-market services in support of moving the needle to benefit patients around the world. The PharmaVoice 100 continues to contain a diverse mix of people across a range of disciplines – from the clinic to the C-suite – who are making meaningful contributions in their fields of influence.

To recognize these honorees and discuss the challenges faced across the life-sciences industry, join PharmaVoice on Sept. 15 for a free, full-day, virtual event. Virtual sessions will take place from 10 a.m. to 3:30 p.m. ET and a virtual celebration for this year’s PharmaVoice 100 honorees, including the surprise reveal of the 2022 Red Jackets, will immediately follow from 3:30 p.m. to 5 p.m. Register and find more details at the event website: 2022 PharmaVoice 100 Celebration: The Next Era of Leadership.

About Structure Therapeutics

Structure Therapeutics is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. By leveraging its next generation structure-based drug discovery platform, the company has built a pipeline including two clinical-stage small molecule compounds designed to overcome the limitations of biologics and peptide therapies. The company is currently focused on the GPCR family of drug targets. For more information, visit www.structuretx.com and follow the company on Twitter @StructureTx and LinkedIn.

About PharmaVoice

PharmaVoice is a leading industry publication operated by Industry Dive. Our stories deliver the most important voices and ideas in the life sciences to industry leaders.

About Industry Dive

Industry Dive is a leading business journalism company. Nearly 13 million decision-makers across 24 competitive industries rely on our exclusive insight and analysis delivered through 27 publications.

Contacts

Media:
Ian Stone

Canale Communications

media@structuretx.com

Other inquiries:
Melita Sun Jung

Chief Business Officer

info@structuretx.com